Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Idit Peretz"'
Autor:
Ofer Rotem, Karyn Revital Geiger, Ekaterina Hanovich, Mor Moskovitz, Noga Kurman, Daniel Reinhorn, Idit Peretz, Rinat Yerushalmi, Salomon M. Stemmer
Publikováno v:
Oncology Reviews, Vol 18 (2024)
As clinical trials in oncology require substantial efforts, maximizing the insights gained from them by conducting subgroup analyses is often attempted. The goal of these analyses is to identify subgroups of patients who are likely to benefit, as wel
Externí odkaz:
https://doaj.org/article/18f293ed166a48a39dded36cb9ce5bf3
Autor:
Ofer Rotem, Idit Peretz, Michelle Leviov, Iryna Kuchuk, Amit Itay, Margarita Tokar, Shani Paluch-Shimon, Ofra Maimon, Rinat Yerushalmi, Karen Drumea, Ella Evron, Amir Sonnenblick, Einav Gal-Yam, Hadar Goldvaser, Yosef Samih, Rotem Merose, Avital Bareket-Samish, Lior Soussan-Gutman, Salomon M. Stemmer
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-8 (2023)
Abstract Data on adjuvant chemotherapy (CT) benefit in ER + HER2‒ early-stage breast cancer (EBC) patients with Recurrence Score (RS) 26-30 are limited. This real-world study evaluated the relationships between the RS, adjuvant treatments, and outc
Externí odkaz:
https://doaj.org/article/ee418dc5761c458bb5099fc02f2cafa0
Autor:
Gino K In, James Larkin, Yazan Samhouri, Marcus Butler, Victoria Atkinson, Jeffrey Chou, Juan Martin-Liberal, Patrick Terheyden, Sajeve Thomas, Wen Shi, Xiao Wu, Andrew S Poklepovic, Young Hong, Giri Sulur, Friedrich Graf Finckenstein, John B Haanen, Andrew JS Furness, Philip Lammers, Ryan H Nguyen, Idit Peretz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/e9124cbb47384a959e3a6d05d13868b4
Autor:
Eldad Elnekave, Eytan Ben Ami, Sivan Shamai, Idit Peretz, Shlomit Tamir, Elchanan Bruckheimer, Amos Stemmer, Joseph Erinjeri, Abed Abu Quider, Max Seidensticker, Moritz Wildgruber, Jens Ricke, Antoinette Anazodo, Kin Fen Fung, Alona Zer, Shifra Ash
Publikováno v:
Cancers, Vol 14, Iss 20, p 5045 (2022)
Desmoid fibromatoses (DFs) are locally aggressive tumors composed of monoclonal fibroblasts within an abundant extracellular matrix. Systemic doxorubicin treatment is effective, but toxic. We investigated arterial doxorubicin eluting embolization (DE
Externí odkaz:
https://doaj.org/article/b237fc9cfd4d402081c043005041f08e
Autor:
Yosef Landman, Oded Jacobi, Noga Kurman, Orly Yariv, Idit Peretz, Ofer Rotem, Elizabeth Dudnik, Alona Zer, Aaron M. Allen
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
The standard of care for stage III non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) followed by durvalumab. Although doses higher than 66 Gy are standard in our center, they were used in only 6.9% of patients in the PACIFIC trial. We rep
Externí odkaz:
https://doaj.org/article/137b1d142eab40229a53b83577ea701c
Autor:
Assaf Moore, Idit Peretz, Lilach Yosef, Daniel A. Goldstein, Hadar Goldvaser, Suzanna Horn, Yonatan Edel, Alona Zer
Publikováno v:
Sarcoma, Vol 2020 (2020)
Background. Kaposi sarcoma is a rare vascular mesenchymal neoplasm, associated with Human Herpes Virus 8 (HHV8). Gout is a condition clinically characterized by recurrent flares of arthritis and hyperuricemia. Following our clinical impression that p
Externí odkaz:
https://doaj.org/article/baa0275d66c44fbda35963729df33f14
Autor:
Eden Verter, Eran Sadot, Yael Berger, Sara Morgenstern, Daniel Benchimol, Idit Peretz, Ana Tovar, Hanoch Kashtan, Baruch Brenner, Gali Perl
Publikováno v:
Annals of Surgical Oncology. 28:4320-4329
Studies have suggested that neutrophil-to-lymphocyte ratio (NLR) has value as a predictor of long-term outcomes in various cancer types. Its prognostic potential in patients with CRLM has not been thoroughly investigated. This original, retrospective
Autor:
Neta, Moskovits, Idit, Peretz, Eva, Chausky, Ella, Itzhaki, Nofar, Shmuel, Raisa, Meerson, Nataly, Tarasenko, Aleksandr, Kaufman, Amos, Stemmer, Ranny, Yaffe, Avital, Bareket-Samish, Natalia, Edison, Tal, Goldman, Salomon M, Stemmer
Publikováno v:
Cancer Letters. 536:215665
The efficacy/safety of combining palbociclib (a CDK4/6 inhibitor) and sunitinib (a multi-targeted receptor tyrosine kinase inhibitor) was evaluated, using patient-derived xenograft (PDX) models. Twenty-three PDX mice models were developed from patien
Publikováno v:
Oncology. 96:14-24
Background: Lymphovascular invasion (LVI) is considered a negative prognostic factor in early breast cancer, but its role in decision-making regarding adjuvant chemotherapy is unclear in the current era of molecular profiling. This study sought to ev
Autor:
Aaron M. Allen, Ofer Rotem, Yosef Landman, Noga Kurman, Orly Yariv, Oded Jacobi, Alona Zer, Idit Peretz, Elizabeth Dudnik
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Oncoimmunology
article-version (VoR) Version of Record
Oncoimmunology
article-version (VoR) Version of Record
The standard of care for stage III non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) followed by durvalumab. Although doses higher than 66 Gy are standard in our center, they were used in only 6.9% of patients in the PACIFIC trial. We rep